ID | 56936 |
JaLCDOI | |
フルテキストURL | |
著者 |
Kitajima, Kazuhiro
Department of Radiology, Division of Nuclear Medicine and PET Center, Hyogo College of Medicine
Yamamoto, Shingo
Department of Urology, Hyogo College of Medicine
Nakanishi, Yukako
Department of Urology, Hyogo College of Medicine
Yamada, Yusuke
Department of Urology, Hyogo College of Medicine
Hashimoto, Takahiko
Department of Urology, Hyogo College of Medicine
Suzuki, Toru
Department of Urology, Hyogo College of Medicine
Go, Shuken
Department of Urology, Hyogo College of Medicine
Kanematsu, Akihiro
Department of Urology, Hyogo College of Medicine
Nojima, Michio
Department of Urology, Hyogo College of Medicine
Fujiwara, Masayuki
Department of Radiology, Hyogo College of Medicine
Kaida, Hayato
Department of Radiology, Kindai University Faculty of Medicine
Tsurusaki, Masakatsu
Department of Radiology, Kindai University Faculty of Medicine
Kanda, Tomonori
Department of Radiology, Kobe University Graduate School of Medicine
Tamaki, Yukihisa
Department of Radiation Oncology, Shimane University School of Medicine
Yamakado, Koichiro
Department of Radiology, Hyogo College of Medicine
|
抄録 | We investigated the effectiveness of 11C-choline-positron emission tomography/computed tomography (PET/CT) for evaluating treatment response in patients with prostate cancer or renal cell carcinoma. We performed 34 11C-choline PET/CT scans before/after a combined total of 17 courses of treatment in 6 patients with prostate cancer and 2 with renal cell carcinoma. The 17 treatments including hormonal therapy, radiotherapy, chemotherapy, radium-223, molecular target therapy, radiofrequency ablation, transcatheter arterial embolization, and cancer immunotherapy yielded 1 (5.9%) complete metabolic response (CMR), 3 (17.6%) partial metabolic responses (PMRs), 2 (11.8%) stable metabolic diseases (SMDs), and 11 (64.7%) progressive metabolic diseases (PMDs). Target lesions were observed in bone (n=14), lymph nodes (n=5), lung (n=2), prostate (n=2), and pleura (n=1), with CMR in 4, PMR in 10, SMD in 8 and PMD in 2 lesions. SUVmax values of the target lesions before and after treatment were 7.87±2.67 and 5.29±3.98, respectively, for a mean reduction of −35.4±43.6%. The response for the 8 prostate cancer-treatment courses was PMD, which correlated well with changes in serum prostatic specific antigen (PSA) (7 of 8 cases showed increased PSA). 11C-choline-PET/CT may be an effective tool for detecting viable residual tumors and evaluating treatment response in prostate cancer and renal cell carcinoma patients.
|
キーワード | treatment response
11C-choline PET/CT
prostate cancer
renal cell carcinoma
|
Amo Type | Original Article
|
出版物タイトル |
Acta Medica Okayama
|
発行日 | 2019-08
|
巻 | 73巻
|
号 | 4号
|
出版者 | Okayama University Medical School
|
開始ページ | 341
|
終了ページ | 347
|
ISSN | 0386-300X
|
NCID | AA00508441
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
著作権者 | CopyrightⒸ 2019 by Okayama University Medical School
|
論文のバージョン | publisher
|
査読 |
有り
|
PubMed ID |